Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Mescaline/Autism Spectrum Disorder (ASD)

Mescaline for Autism Spectrum Disorder (ASD)

1 paper and 0 clinical trials exploring mescaline as a treatment for autism spectrum disorder (asd).

CompoundPhenethylamine

Mescaline

A naturally occurring phenethylamine psychedelic found in certain cacti, investigated for its role in religious practice and psychiatric research.

Full Mescaline profile
IndicationApproximately 1 in 160 children worldwide.

Autism Spectrum Disorder (ASD)

Research into the use of psychedelics for treating Autism Spectrum Disorder (ASD) is limited but gaining traction, with preliminary studies suggesting potential therapeutic benefits, particularly for associated social anxiety. Notable figures in this emerging field, such as Alicia Danforth and Charles Grob, are advocating for further exploration of psychedelics in ASD treatment.

Full Autism Spectrum Disorder (ASD) profile

Academic Research

1 paper
Paywallindividual

Autistic Schizophrenic Children: An Experiment in the Use of D-Lysergic Acid Diethyladmide (LSD-25)

This early study (1962; n=12) with LSD (50-200µg) on children with autism (ASD) and schizophrenia, of which 7 were mute, showed that LSD elicited large psychological changes in this population, but no change in muteness. Procedures for consent were different/non-existent at that time.

Published
March 1, 1962
Journal
JAMA Psychiatry
Authors
Freedman, A. M.

Clinical Trials

0 trials

No clinical trials have been tagged with both Mescaline and Autism Spectrum Disorder (ASD) yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Mescaline papers Search all Autism Spectrum Disorder (ASD) trials Full Mescaline profile Full Autism Spectrum Disorder (ASD) profile